Mosaic ImmunoEngineering, Inc. is a biotechnology company focused on developing immunotherapies for cancer, primarily through licensing and acquisition activities, with limited operational activity and financial resources.

# Company Summary: Mosaic ImmunoEngineering, Inc.

## Business Focus
- **Industry:** Biotechnology, specifically immunotherapies for cancer treatment.
- **Stage:** Development-stage biotechnology company (not yet commercialized products).

## Core Activities
- **Research & Development:** Focused on advancing immunotherapies targeting cancer.
- **Technology Platform:** Historically held rights to the cowpea mosaic virus (CPMV) platform technology, which was intended for treating and preventing cancer and infectious diseases in humans and veterinary use. However, the license agreement for this technology was terminated on March 22, 2024.
- **Product Pipeline:** No active development pipeline currently; efforts are centered on identifying, licensing, or acquiring new product candidates, particularly in immuno-oncology.
- **Partnerships & Acquisitions:** 
  - Entered into a binding term sheet with Oncotelic Therapeutics, Inc. to acquire rights to necroptosis cancer therapies and AI technologies for immunotherapy combinations.
  - Ongoing negotiations for definitive agreements, with the goal of building a pipeline of cancer immunotherapies.

## Business Strategy
- Leverages industry experience and expertise in immunotherapies.
- Aims to license, acquire, and develop new product candidates that address unmet medical needs in cancer.
- Seeks collaborations and licensing agreements, especially for promising technologies and product candidates.

## Financial & Operational Details
- **Number of Employees:** 2 full-time employees and 6 part-time employees as of December 31, 2024 (most inactive due to limited capital).
- **Customer Base & Revenue:**
  - Has not yet developed or approved any commercial products.
  - Earned approximately $42,000 in 2024 from advisory and related services under a Master Services Agreement.
- **Revenue:** No current product revenues; total revenue derived from service income.
- **Income & Losses:**
  - Net loss for 2024: **$921,983**.
  - Net loss for 2023: **$1,008,235**.
- **Assets:** 
  - Cash and cash equivalents: **$115,019** as of December 31, 2024.
  - Total assets: **$141,611** as of December 31, 2024.
- **Liabilities:** 
  - Current liabilities: **$5,537,270**.
  - Total liabilities: **$6,929,785**.

## Corporate Events & Developments
- Conducted reverse merger in August 2020, formerly known as Patriot Scientific Corporation.
- Changed name to Mosaic ImmunoEngineering, Inc.
- Focus shifted away from CPMV platform after termination.
- Entered into multiple agreements for raising capital and licensing, including convertible notes and potential acquisitions.
- No active property holdings; currently operating from home offices at no cost until further capital is raised.

## Summary
Mosaic ImmunoEngineering, Inc. is a biotechnology company focused on developing immunotherapies for cancer, with an emphasis on licensing, acquiring, and developing new product candidates. It has minimal operational activity, limited employees, no current revenue from products, and ongoing negotiations for acquisitions. Its financial position is weak, with significant losses and limited cash, raising substantial doubt about its ability to continue as a going concern.


Mosaic ImmunoEngineering, Inc. is a biotechnology firm focused on developing and commercializing innovative immunotherapies for cancer treatment.

# Summary of Mosaic ImmunoEngineering, Inc.

## Overview
Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company focused on advancing and commercializing immunotherapies for cancer treatment. The company's foundational product candidate, **MIE-101**, is based on a naturally occurring plant virus licensed from **Case Western Reserve University (CWRU)**. 

## Business Focus
1. **Immunotherapy Development**: The primary goal is to develop innovative immunotherapies that can fill unmet medical needs in cancer treatment.
2. **Research Pipeline Expansion**: In addition to MIE-101, Mosaic aims to identify and develop new product candidates, leveraging its expertise in immunotherapy.

## Corporate Structure
- **Incorporated**: Originally incorporated as Patriot Scientific Corporation in 1992, it was renamed Mosaic ImmunoEngineering, Inc. in 2020 following a reverse merger with a private enterprise.
- **Employees**: As of December 31, 2023, the company had **three full-time employees** and **five part-time employees**. The team also relies on various consultants and industry experts for additional support.

## Financials
- **Revenue**: Mosaic has not yet generated any revenue from product sales as it remains in the research and development phase.
- **Net Loss**: The company reported a **net loss of $1,008,235** for the year ended December 31, 2023, compared to a **net loss of $2,380,870** in 2022.
- **Accrued Liabilities**: As of December 31, 2023, the accumulated deficit stood at **$7,916,337**.
- **Funding**: The operations have largely been funded through the issuance of **convertible notes**, raising approximately **$575,000** in 2021 and **$341,632** in 2022. The company also raised **$433,000** and **$343,000** from the redemption of preferred stock from **Holocom, Inc.** in the respective years.

## Customer Base
- Currently, there are **no customers** for product sales since the company's therapies have not yet reached clinical trial stages.

## Critical Challenges
- The company faces significant financial challenges, continuing to seek opportunities for capital investment to advance its development pipeline. As of December 31, 2023, the company had **cash and cash equivalents of $156,178**, insufficient to meet its operational needs for the next twelve months. Thus, it raises substantial doubt regarding its ability to continue as a going concern.

## Conclusion
Mosaic ImmunoEngineering, Inc. is a biotechnology firm in the early stages of product development, dedicated to the commercialization of innovative cancer immunotherapies. While it has built a foundational technology platform, the company continues to grapple with financial uncertainties and must secure additional funding to advance its clinical programs.

Mosaic ImmunoEngineering Inc.

10-K / April 15, 2025

10-K / April 15, 2024

10-K / April 15, 2025

Company Summary: Mosaic ImmunoEngineering, Inc.

Business Focus

Core Activities

Business Strategy

Financial & Operational Details

Corporate Events & Developments

Summary